EA201201208A1 - SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) - Google Patents
SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS)Info
- Publication number
- EA201201208A1 EA201201208A1 EA201201208A EA201201208A EA201201208A1 EA 201201208 A1 EA201201208 A1 EA 201201208A1 EA 201201208 A EA201201208 A EA 201201208A EA 201201208 A EA201201208 A EA 201201208A EA 201201208 A1 EA201201208 A1 EA 201201208A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- action
- solid dosage
- possessing
- options
- solid medicine
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Изобретение относится к области фармацевтической промышленности и медицине и может быть использовано при создании и применении твердых лекарственных форм для лечения и/или профилактики ожирения. Задачей настоящего изобретения является создание эффективной твердой лекарственной формы с использованием сибутрамина гидрохлорида моногидрата, обладающей анорексигенным действием. Задача решается за счет введения в состав твердой лекарственной формы дополнительных минеральных веществ, а также за счет использования изотопов углеродаС и азотаN. Технические результаты: увеличение лечебного эффекта при сохранении продолжительности действия без увеличения концентрации сибутрамина гидрохлорида моногидрата при лечении и/или профилактики ожирения, сокращение времени наступления лечебного эффекта.The invention relates to the pharmaceutical industry and medicine and can be used in the creation and use of solid dosage forms for the treatment and / or prevention of obesity. The present invention is the creation of an effective solid dosage form using sibutramine hydrochloride monohydrate with anorexigenic action. The problem is solved by introducing into the solid dosage form additional minerals, as well as through the use of carbon isotopes and nitrogen. Technical results: increased therapeutic effect while maintaining the duration of action without increasing the concentration of sibutramine hydrochloride monohydrate in the treatment and / or prevention of obesity, reducing the time of onset of therapeutic effect.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201201208A EA020109B1 (en) | 2012-10-01 | 2012-10-01 | Solid dosage form having an anorectic effect (variants) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201201208A EA020109B1 (en) | 2012-10-01 | 2012-10-01 | Solid dosage form having an anorectic effect (variants) |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201201208A1 true EA201201208A1 (en) | 2014-04-30 |
EA020109B1 EA020109B1 (en) | 2014-08-29 |
Family
ID=50516402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201201208A EA020109B1 (en) | 2012-10-01 | 2012-10-01 | Solid dosage form having an anorectic effect (variants) |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA020109B1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8591801A1 (en) * | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | BENZAMID INHIBITORS OF THE P2X7 RECEIVER. |
RU2426443C2 (en) * | 2007-02-23 | 2011-08-20 | Хилл'С Пет Ньютришн, Инк. | Compositions and methods for animal weight control (versions) |
-
2012
- 2012-10-01 EA EA201201208A patent/EA020109B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EA020109B1 (en) | 2014-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020004023A (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia. | |
MX2016005532A (en) | Methods for using nitric oxide in a plasma state to treat medical conditions and diseases. | |
EA201790195A1 (en) | METHODS OF TREATING CANCER WITH THE USE OF TIGIT INHIBITORS AND ANTI-CANCER AGENTS | |
EA201491773A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINATION OF LAKININIMODE AND DIMETYL FUMARATE | |
MX2019006900A (en) | Methods of therapeutic monitoring of nitrogen scavenging drugs. | |
EA201691155A1 (en) | COMBINATION INHIBITORS OF HISTONDEACETYLASE AND IMMUNOMODULATING MEDICINES | |
EA201590703A1 (en) | MEK INHIBITORS FOR TREATING VIRAL DISEASES | |
EA201490378A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS USING THE COMBINATION OF LACHINIMODA AND INTERFERON-β | |
EA201400002A1 (en) | METHODS TO TREAT DISEASES OF THE RETAIL | |
MX392388B (en) | Method of treating or reducing efp | |
PH12018501443A1 (en) | Methods of administering hepcidin | |
EA201490045A1 (en) | DEUTERED 1-PIPERAZINO-3-PHENYLINDANES USED TO TREAT SCHIZOPHRENIA | |
MY180772A (en) | Novel therapeutic mirtazapine combinations for use in pain disorders | |
MX2019007236A (en) | Methods of administering hepcidin. | |
EA201201208A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
GB201115977D0 (en) | Neurodevelopmental disorders | |
EA201201222A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
EA201201209A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
EA201201223A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
EA201201225A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
EA201201224A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
EA201201211A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
EA201201210A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
EA201201207A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) | |
EA201201226A1 (en) | SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |
|
NF4A | Restoration of lapsed right to a eurasian patent |
Designated state(s): RU |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |